Lilly’s Cyramza, after split decision from FDA advisers, wins first-line lung cancer nod

Lilly’s Cyramza, after split decision from FDA advisers, wins first-line lung cancer nod

When an FDA advisory panel narrowly backed Eli Lillys Cyramza for use in newly diagnosed non-small cell lung cancer, a final approval didnt seem so certain. Now, the company can breathe a sigh of rel…
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *